<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="29820">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02718495</url>
  </required_header>
  <id_info>
    <org_study_id>PTI-428-01</org_study_id>
    <nct_id>NCT02718495</nct_id>
  </id_info>
  <brief_title>Study Assessing PTI-428 Safety, Tolerability, and Pharmacokinetics in Subjects With Cystic Fibrosis</brief_title>
  <official_title>A Multi-center, Randomized, Placebo-Controlled, Ascending Dose Phase I Study Designed to Assess the Safety, Tolerability, and Pharmacokinetics of PTI-428 in Subjects With Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Proteostasis Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Proteostasis Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will consist of two parts: the first part will enroll subjects with cystic
      fibrosis (CF) of any mutation into a single ascending dose (SAD) treatment group. The second
      part will enroll adult subjects with CF of any mutation into a multiple ascending dose (MAD)
      treatment group. At least 36 subjects will be enrolled.

      The SAD treatment group is comprised of at least 3 cohorts where subjects will be randomized
      to either PTI-428 or placebo while being housed at or close to the clinical site checking in
      on Day -1 and staying through Day 4. Subjects will return to the clinical site on Day 7 for
      a final follow-up visit. The Safety Review Committee (SRC) will convene after the completion
      of each cohort to evaluate safety and other relevant data. The decision on whether to
      escalate the dose will be made for a completed cohort.

      Following the conclusion of at least 3 SAD treatment groups and after sufficient review of
      study data and approval by the SRC, a second set of adult subjects diagnosed with cystic
      fibrosis will participate in an assigned MAD treatment group. The MAD treatment group is
      comprised of at least 3 cohorts where subjects will be randomized to either PTI-428 or
      placebo while being housed at or close to the clinical site checking in on Day -1 and
      staying through Day 4. Subjects will return to the clinical site daily on Days 5-10 and Day
      12 for an outpatient follow up visit. Subjects will return to clinic on Day 14 for the final
      follow-up visit. Each dose will be administered once daily (QD) for a total of 7 Days. The
      SRC will convene after the completion of each cohort to evaluate safety and other relevant
      data. The decision on whether to escalate the dose will be made for a completed cohort.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SAD: Safety and tolerability measured by number of subjects who experience adverse events and potential clinically significant changes in safety labs, electrocardiograms (ECGs), physical examinations, and vital signs.</measure>
    <time_frame>baseline to 7 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>MAD: Safety and tolerability measured by number of subjects who experience adverse events and potential clinically significant changes in pulmonary function tests, safety labs, ECGs, physical examinations, and vital signs.</measure>
    <time_frame>baseline to 14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>SAD: Apparent terminal half-life (t1/2) of single oral dose</measure>
    <time_frame>through 72-hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAD: Time to reach maximum plasma concentration (Tmax) of single oral dose</measure>
    <time_frame>through 72-hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAD: Maximum plasma concentration (Cmax) of single oral dose</measure>
    <time_frame>through 72-hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAD: Area under the concentration-time curve from time 0 to time of last measurable concentration (AUC0-t) of single oral dose</measure>
    <time_frame>through 72-hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAD: Apparent terminal half-life (t1/2) of multiple oral doses</measure>
    <time_frame>through 72 hours post day 7 dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAD: Time to reach maximum plasma concentration (Tmax) of multiple oral doses</measure>
    <time_frame>through 72 hours post day 7 dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAD: Maximum plasma concentration (Cmax) of multiple oral doses</measure>
    <time_frame>through 72 hours post day 7 dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAD: Area under the concentration-time curve from time 0 to time of last measurable concentration (AUC0-t) of multiple oral doses</measure>
    <time_frame>through 72 hours post day 7 dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAD: Area under the concentration-time curve from time 0 to infinity (AUC0-âˆž) of multiple oral doses</measure>
    <time_frame>through 72 hours post day 7 dose</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>SAD: Change from baseline in cystic fibrosis transmembrane conductance regulator (CFTR) expression.</measure>
    <time_frame>baseline to 7 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>MAD: Change from baseline in CFTR expression.</measure>
    <time_frame>baseline to 14 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>MAD: Change from baseline in sweat chloride concentration.</measure>
    <time_frame>baseline to 14 days</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>SAD Cohort</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>a minimum of 3 cohorts are planned. Subjects will receive a single dose of PTI-428 or placebo and will be followed for 7 days post dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Cohort</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>a minimum of 3 cohorts are planned. Subjects will receive once daily dosing of PTI-428 or placebo for 7 days and will be followed through Day 14 (7 days after the last dose of study drug).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PTI-428</intervention_name>
    <arm_group_label>SAD Cohort</arm_group_label>
    <arm_group_label>MAD Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>SAD Cohort</arm_group_label>
    <arm_group_label>MAD Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of CF.

          -  Forced expiratory volume in 1 second (FEV1) &gt;50% predicted pre-bronchodilator.

          -  Non-smoker and non-tobacco user for a minimum of 30 days prior to screening and for
             the duration of the study.

        Exclusion Criteria:

          -  Participation in another clinical trial or treatment with an investigational agent
             within 30 days or 5 half-lives, whichever is longer, prior to Study Day 1.

          -  History of cancer within the past five years (excluding non-melanoma skin cancer).

          -  History of organ transplantation.

          -  History of alcohol or drug abuse or dependence within 12 months of screening as
             determined by the Investigator.

          -  Male and female of child-bearing potential, unless they are using highly effective
             methods of contraception during participation in the clinical study and for 4 weeks
             after termination from study.

          -  Pregnant or nursing women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Courtney Watson</last_name>
    <phone>+ 1 207-807-0211</phone>
    <email>Courtney.watson@proteostasis.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colleen Dunn</last_name>
      <email>cedunn@stanford.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Altamonte Springs</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Billy Fortson</last_name>
      <phone>407-481-1100</phone>
      <phone_ext>173</phone_ext>
      <email>bfortson@cfpulmonary.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noni A. Graham, MPH</last_name>
      <phone>352-294-5195</phone>
      <email>Noni.Graham@medicine.ufl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mary E Teresi, Pharm.D.</last_name>
      <email>Mary-teresi@uiowa.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Kreisler, CCRC</last_name>
      <phone>913 894-5533</phone>
      <email>Amy.Kreisler@quintiles.com</email>
    </contact>
    <contact_backup>
      <last_name>Lisa Vansaghi, MD</last_name>
      <phone>913 894-5533</phone>
      <email>Lisa.Vansaghi@quintiles.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Penny</last_name>
      <phone>502-629-5820</phone>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Fowler</last_name>
      <email>robert.fowler@childrens.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samya Nasr, M.D.</last_name>
      <phone>734-764-4123</phone>
      <email>snasr@umich.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vicki Dean, RN</last_name>
      <email>dean.vicki@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Marsh Pike, RN</last_name>
      <email>pike.marsha@mayo.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gloria Pinero</last_name>
      <phone>919-684-2281</phone>
      <email>gloria.pinero@duke.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jodie Fox</last_name>
      <email>Jodie-Fox@ouhsc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amber Kriger</last_name>
      <phone>843-792-6648</phone>
      <email>kriger@musc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Patrick Flume, M.D.</last_name>
      <email>flumepa@musc.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Tolle, M.D.</last_name>
      <phone>615-322-2386</phone>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston</city>
        <state>West Virginia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leena Rizvi</last_name>
      <phone>416.864.6060</phone>
      <phone_ext>2938</phone_ext>
      <email>rizvil@smh.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 28, 2016</lastchanged_date>
  <firstreceived_date>March 10, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
